Evidence map›Paper›PMID 42306568›Full record

ArticleMolecular therapy. Oncology2026

Targeting SMYD2 improves immunotherapy response in experimental hepatocellular carcinoma.

Bárbara Bueloni, Mariel Fusco, Esteban Fiore, Mariana Malvicini, María Jose Cantero, Lucía Lameroli, Mailín Casadei, Brian Martinez Ruiz, Florencia Mercogliano, Eva Santamaría and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Bárbara BueloniHepatology and Gene Therapy Program, Instituto de Investigaciones en Medicina Traslacional, CONICET - Universidad Austral, Av. Pte. Perón 1500, B1629AHJ, Pilar, Provincia de Buenos Aires, Buenos Aires, Argentina.
Mariel FuscoFacultad de Ciencias Biomédicas, Universidad Austral, Av. Pte. Perón 1500, B1629AHJ, Pilar, Buenos Aires, Argentina.
Esteban FioreHepatology and Gene Therapy Program, Instituto de Investigaciones en Medicina Traslacional, CONICET - Universidad Austral, Av. Pte. Perón 1500, B1629AHJ, Pilar, Provincia de Buenos Aires, Buenos Aires, Argentina.
Mariana MalviciniFacultad de Ciencias Biomédicas, Universidad Austral, Av. Pte. Perón 1500, B1629AHJ, Pilar, Buenos Aires, Argentina.
María Jose CanteroHepatology and Gene Therapy Program, Instituto de Investigaciones en Medicina Traslacional, CONICET - Universidad Austral, Av. Pte. Perón 1500, B1629AHJ, Pilar, Provincia de Buenos Aires, Buenos Aires, Argentina.
Lucía LameroliHepatology and Gene Therapy Program, Instituto de Investigaciones en Medicina Traslacional, CONICET - Universidad Austral, Av. Pte. Perón 1500, B1629AHJ, Pilar, Provincia de Buenos Aires, Buenos Aires, Argentina.
Mailín CasadeiHepatology and Gene Therapy Program, Instituto de Investigaciones en Medicina Traslacional, CONICET - Universidad Austral, Av. Pte. Perón 1500, B1629AHJ, Pilar, Provincia de Buenos Aires, Buenos Aires, Argentina.
Brian Martinez RuizHepatology and Gene Therapy Program, Instituto de Investigaciones en Medicina Traslacional, CONICET - Universidad Austral, Av. Pte. Perón 1500, B1629AHJ, Pilar, Provincia de Buenos Aires, Buenos Aires, Argentina.
Florencia MercoglianoConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. Rivadavia 1917, C1033AAJ, Buenos Aires, Argentina.
Eva SantamaríaDNA and RNA Medicine Division, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain.
Catalina AtorrasagastiHepatology and Gene Therapy Program, Instituto de Investigaciones en Medicina Traslacional, CONICET - Universidad Austral, Av. Pte. Perón 1500, B1629AHJ, Pilar, Provincia de Buenos Aires, Buenos Aires, Argentina.
Josepmaria ArgemiDNA and RNA Medicine Division, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain.
Ali CanbayDepartment of Internal Medicine, Ruhr-Universitat Bochum, 44801 Bochum, Germany.
Juan BayoHepatology and Gene Therapy Program, Instituto de Investigaciones en Medicina Traslacional, CONICET - Universidad Austral, Av. Pte. Perón 1500, B1629AHJ, Pilar, Provincia de Buenos Aires, Buenos Aires, Argentina.
Guillermo MazzoliniHepatology and Gene Therapy Program, Instituto de Investigaciones en Medicina Traslacional, CONICET - Universidad Austral, Av. Pte. Perón 1500, B1629AHJ, Pilar, Provincia de Buenos Aires, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic options for hepatocellular carcinoma (HCC) remain scarce and limited by resistance, underscoring the need for novel approaches. The lysine methyltransferase SMYD2 is overexpressed in several cancers and regulates oncogenic signaling through histone and non-histone substrates. However, its role in HCC is incompletely defined. We integrated transcriptomic analyses of patient samples with

Indexed as

beta-cateninimmunosuppressionlysine methyltransferasemacrophage polarizationpharmacological inhibitionTGF-β pathwaytumor microenvironmentWnt signaling

Identifiers

PMID42306568
PMCPMC13266103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.